(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Non-Hodgkin Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.
The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.
- Non-Hodgkin Lymphoma companies working in the treatment market are AbbVie, Novartis, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Autolus, Genor Biopharma, Genmab, Loxo Oncology, Angiocrine Bioscience, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment
- Emerging Non-Hodgkin Lymphoma therapies such as – HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, AUTO4, GB226, Epcoritamab, Capivasertib, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.
- In August 2021, HUTCHMED Limited and Epizyme, Inc. announced a collaboration to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan
- Naratuximab emtansine (Debio 1562), an antibody-drug conjugate (ADC) targeting CD37, is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin’s lymphomas (NHL)
- In May 2019, Novartis initiated a a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell NonHodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immune chemotherapy
Non-Hodgkin Lymphoma Overview
Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphatic system. It occurs when tumors develop from the lymphocytes. Alymphocyte is a type of white blood cell. NHL is more common than Hodgkin’s lymphoma.
Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment
Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
- HRS-3738: Jiangsu Hengrui Medicine
- PCLX-001: Pacylex Pharmaceuticals
- ZN-d5: Zentera Therapeutics
- TC-110: TCR2 Therapeutics
- AB-101: Artiva Biotherapeutics
- AUTO4: Autolus
- GB226: Genor Biopharma
- Epcoritamab: AbbVie/ Genmab
- Capivasertib: AstraZeneca
- LOXO-305: Loxo Oncology
- AB-205: Angiocrine Bioscience
- Venetoclax: AbbVie
- Tisagenlecleucel: Novartis
Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
- Non-Hodgkin Lymphoma Assessment by Product Type
- Non-Hodgkin Lymphoma By Stage and Product Type
- Non-Hodgkin Lymphoma Assessment by Route of Administration
- Non-Hodgkin Lymphoma By Stage and Route of Administration
- Non-Hodgkin Lymphoma Assessment by Molecule Type
- Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight’s Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies
Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:
Key companies developing therapies for Non-Hodgkin Lymphoma are – Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, and others.
Non-Hodgkin Lymphoma Pipeline Analysis:
The Non-Hodgkin Lymphoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
- Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies
Non-Hodgkin Lymphoma Pipeline Market Drivers
- Increasing Non-Hodgkin Lymphoma prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.
Non-Hodgkin Lymphoma Pipeline Market Barriers
- However, high cost of Non-Hodgkin Lymphoma treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.
Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight
- Coverage: Global
- Key Non-Hodgkin Lymphoma Companies: AbbVie, Novartis, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Autolus, Genor Biopharma, Genmab, Loxo Oncology, Angiocrine Bioscience, and others
- Key Non-Hodgkin Lymphoma Therapies: HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, AUTO4, GB226, Epcoritamab, Capivasertib, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
- Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
- Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials
Table of Contents
| 1 | Non-Hodgkin Lymphoma Report Introduction |
| 2 | Non-Hodgkin Lymphoma Executive Summary |
| 3 | Non-Hodgkin Lymphoma Overview |
| 4 | Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment |
| 5 | Non-Hodgkin Lymphoma Pipeline Therapeutics |
| 6 | Non-Hodgkin Lymphoma Late Stage Products (Phase II/III) |
| 7 | Non-Hodgkin Lymphoma Mid Stage Products (Phase II) |
| 8 | Non-Hodgkin Lymphoma Early Stage Products (Phase I) |
| 9 | Non-Hodgkin Lymphoma Preclinical Stage Products |
| 10 | Non-Hodgkin Lymphoma Therapeutics Assessment |
| 11 | Non-Hodgkin Lymphoma Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Non-Hodgkin Lymphoma Key Companies |
| 14 | Non-Hodgkin Lymphoma Key Products |
| 15 | Non-Hodgkin Lymphoma Unmet Needs |
| 16 | Non-Hodgkin Lymphoma Market Drivers and Barriers |
| 17 | Non-Hodgkin Lymphoma Future Perspectives and Conclusion |
| 18 | Non-Hodgkin Lymphoma Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Related Reports:
DelveInsight’s ‘Non-Hodgkin Lymphoma-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Non-Hodgkin Lymphoma Epidemiology
DelveInsight’s ‘Non-Hodgkin Lymphoma Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog’s By DelveInsight:
Trending Reports:
- Thymic Carcinoma Market
- Neurostimulation Devices Market
- Osteoarthritis Market
- Sjogren’s Syndrome Market
- Hemodynamic Monitoring Systems Market
- Pediatric Obesity Market
- Global Electrophysiology Devices Market
- Acute Radiation Syndrome Market
- Bone Anchored Hearing Systems Market
- Bronchial Spasm Market
- Complicated Intra-Abdominal Infections Market
- Dermal Erythema Market
- Hip Replacement Devices Market
- Hpv-Induced Cancers Market
- Interbody Cages Market
- Meningioma Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187